{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:38:24Z","timestamp":1777415904203,"version":"3.51.4"},"reference-count":105,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma is the most commonly diagnosed subtype of lymphoma worldwide. The current World Health Organization (WHO) classification includes several subtypes, based on a combination of clinical, immunohistochemical, and genetic differences. Immunohistochemical staining is essential in evaluating diffuse large B-cell lymphoma and many related large B-cell lymphomas and aggressive B-cell lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To address different immunohistochemical features used for identification, subclassification, prognosis and in some cases, therapy, of diffuse large B-cell lymphoma and related lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>The information outlined in this review article is based on our experiences with routine cases, on the current WHO classification of hematopoietic and lymphoid tumors, and on a review of English-language articles published throughout 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Features and diagnostic criteria of diffuse large B-cell lymphoma, aggressive variants of B-cell lymphomas, including Burkitt lymphoma and \u201cdouble-hit\u201d lymphomas, are discussed. Identification of cell of origin (germinal center type versus activated B-cell type) is discussed at length. Finally, practical approaches for diagnosis are discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2014-0451-cp","type":"journal-article","created":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T17:33:05Z","timestamp":1420219985000},"page":"1094-1107","source":"Crossref","is-referenced-by-count":30,"title":["Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas"],"prefix":"10.5858","volume":"139","author":[{"given":"Dennis P.","family":"O'Malley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Auerbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence M.","family":"Weiss","sequence":"additional","affiliation":[{"name":"From Clarient Diagnostic Services, Aliso Viejo, California (Drs O'Malley and Weiss); and Joint Pathology Center, Silver Spring, Maryland (Dr Auerbach)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2015,1,2]]},"reference":[{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b01","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin's lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b02","unstructured":"Alberta Provincial Hematology Tumour Team. Clinical practice guideline LYHE-002: Lymphoma. Edmonton, Alberta: Alberta Health Services, Cancer Care. September 2012. http:\/\/www.albertahealthservices.ca\/hp\/if-hp-cancer-guide-lyhe002-lymphoma.pdf. Accessed October 21, 2014."},{"key":"2020081216435397500_i1543-2165-139-9-1094-b03","unstructured":"Duncavage\n              E, \n            \n              Advani\n              RH, \n            \n              Agosti\n              S, \n            et al\n          . Template for reporting results of biomarker testing from patients with diffuse large b-cell lymphoma, not otherwise specified (NOS). Northfield, IL: College of American Pathologists. 2014. http:\/\/www.cap.org\/ShowProperty?nodePath=\/UCMCon\/Contribution%20Folders\/WebContent\/pdf\/cp-diffuse-large-b-cell-lymphoma-biomarker-14.pdf. Accessed June 30, 2015."},{"key":"2020081216435397500_i1543-2165-139-9-1094-b04","unstructured":"Swerdlow\n              SH, \n            \n              Campo\n              E, \n            \n              Harris\n              NL, \n          \n          et al, eds. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2008;194\u2013195. World Health Organization Classification of Tumours; vol 2."},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b05","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jclinpath-2013-201619","article-title":"Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma","volume":"66","author":"Frei","year":"2013","journal-title":"J Clin Pathol"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b06","first-page":"301","article-title":"Thymidine phosphorylase expression in B-cell lymphomas and its significance: a new prognostic marker?","volume":"35","author":"Nie","year":"2013","journal-title":"Anal Quant Cytol Histol"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b07","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/his.12162","article-title":"Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma","volume":"63","author":"Lilja","year":"2013","journal-title":"Histopathology"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b08","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/PAS.0000000000000094","article-title":"TNF-\u03b1 expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified","volume":"38","author":"Nakayama","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b09","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/cas.12215","article-title":"Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP","volume":"104","author":"Koh","year":"2013","journal-title":"Cancer Sci"},{"issue":"10","key":"2020081216435397500_i1543-2165-139-9-1094-b10","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00277-013-1775-4","article-title":"Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma","volume":"92","author":"Bedewy","year":"2013","journal-title":"Ann Hematol"},{"issue":"7","key":"2020081216435397500_i1543-2165-139-9-1094-b11","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.humpath.2012.10.026","article-title":"MYD88 expression and L265P mutation in diffuse large B-cell lymphoma","volume":"44","author":"Choi","year":"2013","journal-title":"Hum Pathol"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/leu.2012.367","article-title":"MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma","volume":"27","author":"Wenzel","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2020081216435397500_i1543-2165-139-9-1094-b13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/10428194.2013.793324","article-title":"IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1)","volume":"55","author":"Tinguely","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b14","first-page":"911","article-title":"Overexpression of IL-9 receptor in diffuse large B-cell lymphoma","volume":"6","author":"Lv","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"issue":"13","key":"2020081216435397500_i1543-2165-139-9-1094-b15","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7360","key":"2020081216435397500_i1543-2165-139-9-1094-b16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-12-10","article-title":"Frequent copy number variations of PI3K\/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma","volume":"12","author":"Cui","year":"2014","journal-title":"J Transl Med"},{"issue":"7","key":"2020081216435397500_i1543-2165-139-9-1094-b18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Montes-Moreno","year":"2012","journal-title":"Mod Pathol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b19","first-page":"233","article-title":"Diffuse large B cell lymphoma, not otherwise specified","author":"Stein","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V83.6.1460.1460","article-title":"Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial","volume":"83","author":"Miller","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2559.2006.02378.x","article-title":"Ki-67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders","volume":"48","author":"Bryant","year":"2006","journal-title":"Histopathology"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2559.2012.04351.x","article-title":"Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?","volume":"61","author":"Mationg-Kalaw","year":"2012","journal-title":"Histopathology"},{"issue":"24","key":"2020081216435397500_i1543-2165-139-9-1094-b23","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1158\/1078-0432.CCR-11-0267","article-title":"BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab","volume":"17","author":"Iqbal","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"28","key":"2020081216435397500_i1543-2165-139-9-1094-b24","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020081216435397500_i1543-2165-139-9-1094-b25","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2020081216435397500_i1543-2165-139-9-1094-b26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/modpathol.2010.76","article-title":"Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas","volume":"23","author":"Seegmiller","year":"2010","journal-title":"Mod Pathol"},{"issue":"8","key":"2020081216435397500_i1543-2165-139-9-1094-b27","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b28","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1080\/10428190600687547","article-title":"Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis","volume":"47","author":"Mossafa","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PAT.0000000000000076","article-title":"Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis","volume":"46","author":"Lynnhtun","year":"2014","journal-title":"Pathology"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2559.2011.03978.x","article-title":"Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas","volume":"59","author":"Tapia","year":"2011","journal-title":"Histopathology"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033813","article-title":"Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas","volume":"7","author":"Kluk","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b33","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2020081216435397500_i1543-2165-139-9-1094-b34","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/cncr.28664","article-title":"Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"120","author":"Ok","year":"2014","journal-title":"Cancer"},{"issue":"(3","key":"2020081216435397500_i1543-2165-139-9-1094-b35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10428194.2010.540361","article-title":"Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus","volume":"52","author":"Vela-Ch\u00e1vez","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2020081216435397500_i1543-2165-139-9-1094-b36","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b37","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3109\/10428194.2013.778407","article-title":"Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases","volume":"54","author":"Campuzano-Zuluaga","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mayocp.2011.11.007","article-title":"My treatment approach to patients with diffuse large B-cell lymphoma","volume":"87","author":"Armitage","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"2020081216435397500_i1543-2165-139-9-1094-b39","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"issue":"6769","key":"2020081216435397500_i1543-2165-139-9-1094-b40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"36","key":"2020081216435397500_i1543-2165-139-9-1094-b41","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"2020081216435397500_i1543-2165-139-9-1094-b42","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"2020081216435397500_i1543-2165-139-9-1094-b43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"issue":"8","key":"2020081216435397500_i1543-2165-139-9-1094-b44","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/PAS.0000000000000211","article-title":"High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large b-cell lymphoma, not otherwise specified","volume":"38","author":"Hwang","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"2020081216435397500_i1543-2165-139-9-1094-b45","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b46","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","article-title":"Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era [published online ahead of print March 13, 2014]","volume":"25","author":"Vaidya","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2020081216435397500_i1543-2165-139-9-1094-b47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b48","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma","volume":"208","author":"Muris","year":"2006","journal-title":"J Pathol"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","article-title":"LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab","volume":"26","author":"Natkunam","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020081216435397500_i1543-2165-139-9-1094-b50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/modpathol.2009.73","article-title":"Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"22","author":"Nyman","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b52","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"2020081216435397500_i1543-2165-139-9-1094-b53","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b54","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/his.12223","article-title":"Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients","volume":"63","author":"Culpin","year":"2013","journal-title":"Histopathology"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdn793","article-title":"CD5 expression in de novo diffuse large B-cell lymphomas","volume":"20","author":"Went","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ajh.23467","article-title":"Recent advances in de novo CD5+ diffuse large B cell lymphoma","volume":"88","author":"Jain","year":"2013","journal-title":"Am J Hematol"},{"issue":"8","key":"2020081216435397500_i1543-2165-139-9-1094-b57","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0145-2126(03)00253-4","article-title":"T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma","volume":"28","author":"Aki","year":"2004","journal-title":"Leuk Res"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b59","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428190701559124","article-title":"T-cell\/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature","volume":"48","author":"El Weshi","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00428-011-1165-z","article-title":"T cell\/histiocyte-rich large B-cell lymphoma: an update on its biology and classification","volume":"459","author":"Tousseyn","year":"2011","journal-title":"Virchows Arch"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078812","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma: endpoints of a spectrum of one disease?","volume":"8","author":"Hartmann","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.humpath.2008.10.007","article-title":"Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype","volume":"40","author":"Gibson","year":"2009","journal-title":"Hum Pathol"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b63","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2009.07.024","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations","volume":"41","author":"Hoeller","year":"2010","journal-title":"Hum Pathol"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PAP.0b013e318229bf08","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly","volume":"18","author":"Adam","year":"2011","journal-title":"Adv Anat Pathol"},{"issue":"9","key":"2020081216435397500_i1543-2165-139-9-1094-b65","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of Epstein-Barr Virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10428190902725813","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly","volume":"50","author":"Wong","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b67","first-page":"262","article-title":"Burkitt lymphoma","author":"Leoncini","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"suppl 1","key":"2020081216435397500_i1543-2165-139-9-1094-b68","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1038\/modpathol.2012.182","article-title":"Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications","volume":"26","author":"Harris","year":"2013","journal-title":"Mod Pathol"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b69","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2020081216435397500_i1543-2165-139-9-1094-b70","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b71","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/modpathol.3800440","article-title":"Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas","volume":"18","author":"Zam\u00f2","year":"2005","journal-title":"Mod Pathol"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2559.2009.03462.x","article-title":"BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma","volume":"56","author":"Hoeller","year":"2010","journal-title":"Histopathology"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5858\/arpa.2010-0747-RS","article-title":"Intravascular large B-cell lymphoma","volume":"136","author":"Orwat","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"21","key":"2020081216435397500_i1543-2165-139-9-1094-b74","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020081216435397500_i1543-2165-139-9-1094-b75","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/PAS.0b013e3182515fb5","article-title":"Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammation?","volume":"36","author":"Boroumand","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/modpathol.2009.168","article-title":"Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios","volume":"23","author":"Loong","year":"2010","journal-title":"Mod Pathol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b77","first-page":"245","article-title":"DLBCL associated with chronic inflammation","author":"Chan","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b78","first-page":"247","article-title":"Lymphomatoid granulomatosis","author":"Pittaluga","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/PPO.0b013e31826c5e19","article-title":"Lymphomatoid granulomatosis","volume":"18","author":"Roschewski","year":"2012","journal-title":"Cancer J"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b80","first-page":"254","article-title":"ALK-positive large B cell lymphoma","author":"Delsol","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"25","key":"2020081216435397500_i1543-2165-139-9-1094-b81","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b82","doi-asserted-by":"crossref","first-page":"529572","DOI":"10.1155\/2012\/529572","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma","volume":"2012","author":"Morgan","year":"2012","journal-title":"Adv Hematol"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10428194.2011.608447","article-title":"Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge","volume":"53","author":"Montes-Moreno","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/ejh.12240","article-title":"Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response","volume":"92","author":"Wass","year":"2014","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1309\/AJCPV1I2QWKZKNJH","article-title":"Plasmablastic lymphoma and related disorders","volume":"136","author":"Hsi","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b86","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28923","article-title":"KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies","author":"Carbone","year":"2014]","journal-title":"Int J Cancer"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b88","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12308-012-0148-6","article-title":"Early lesions in lymphoid neoplasia","volume":"5","author":"Fend","year":"2012","journal-title":"J Hematopathol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b89","first-page":"214","article-title":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease","author":"Isaacson","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"12","key":"2020081216435397500_i1543-2165-139-9-1094-b90","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3109\/10428194.2012.694075","article-title":"Prognosis in primary effusion lymphoma is associated with the number of body cavities involved","volume":"53","author":"Castillo","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000097460","article-title":"Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature","volume":"117","author":"Kobayashi","year":"2007","journal-title":"Acta Haematol"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b92","first-page":"260","article-title":"Primary effusion lymphoma","author":"Said","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"11","key":"2020081216435397500_i1543-2165-139-9-1094-b93","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cncy.21311","article-title":"Kaposi sarcoma herpesvirus\/human herpesvirus-8-negative effusion-based lymphoma: report of 3 cases and review of the literature","volume":"121","author":"Xiao","year":"2013","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"2020081216435397500_i1543-2165-139-9-1094-b94","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.2011.08771.x","article-title":"Diagnosis of Burkitt lymphoma using an algorithmic approach applicable in both resource-poor and resource-rich countries","volume":"154","author":"Naresh","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2020081216435397500_i1543-2165-139-9-1094-b95","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAP.0b013e3182a289f2","article-title":"MYC\/BCL2 double-hit high-grade B-cell lymphoma","volume":"20","author":"Li","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"10","key":"2020081216435397500_i1543-2165-139-9-1094-b96","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/modpathol.2014.34","article-title":"NF\u03baB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"27","author":"Odqvist","year":"2014","journal-title":"Mod Pathol"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b97","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2020081216435397500_i1543-2165-139-9-1094-b98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"2020081216435397500_i1543-2165-139-9-1094-b99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11899-013-0169-y","article-title":"The impact of MYC rearrangements and \u201cdouble hit\u201d abnormalities in diffuse large B-cell lymphoma","volume":"8","author":"Lin","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"2020081216435397500_i1543-2165-139-9-1094-b100","first-page":"267","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma","author":"Jaffe","year":"2008","journal-title":"WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues"},{"issue":"2","key":"2020081216435397500_i1543-2165-139-9-1094-b101","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review","volume":"119","author":"Kennedy","year":"2002","journal-title":"Br J Haematol"},{"issue":"12","key":"2020081216435397500_i1543-2165-139-9-1094-b102","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/1042819021000040044","article-title":"Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study","volume":"43","author":"Chu","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"84","key":"2020081216435397500_i1543-2165-139-9-1094-b103","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-84","article-title":"CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution","volume":"10","author":"Li","year":"2012","journal-title":"J Transl Med"},{"issue":"7","key":"2020081216435397500_i1543-2165-139-9-1094-b104","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","article-title":"CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab","volume":"22","author":"Miyazaki","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"2020081216435397500_i1543-2165-139-9-1094-b105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical significance of MYC expression and\/or \u201chigh-grade\u201d morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/9\/1094\/1613725\/arpa_2014-0451-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/9\/1094\/1613725\/arpa_2014-0451-cp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:37:02Z","timestamp":1764790622000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/9\/article-p1094.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,2]]},"references-count":105,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,1,2]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0451-cp","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,2]]}}}